Drug profile · INN
tolvaptan
JINARC
tolvaptan (JINARC) is a vasopressin v2 receptor antagonist. Associated with Otsuka Beijing Research Institute. Route of administration: oral. Current US regulatory status: approved.
Drug details — tolvaptan
- US status
- approved
- Class
- Cardiovascular system (C03)
- Route
- ORAL
- Patents
- 0
- Programs
- 5
- Data quality
- 0.84
Quick answer
tolvaptan (JINARC) is a vasopressin v2 receptor antagonist. Associated with Otsuka Beijing Research Institute. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Vasopressin V2 receptor antagonist
Primary target: Vasopressin V2 receptor
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| EMA | approved | — |
| TGA | approved | — |
| PMDA | approved | — |
| NMPA | clinical trials | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is tolvaptan?
tolvaptan (JINARC) is a vasopressin v2 receptor antagonist. Associated with Otsuka Beijing Research Institute. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for tolvaptan?
JINARC is a marketed brand name for tolvaptan. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of tolvaptan?
tolvaptan has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.